1stOncology™: Cancer Intelligence Service – Page 15057 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

CytRx Corporation to Hold Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018

On July 30, 2018 CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, reported that it will report financial results for the quarter ended June 30, 2018 on Monday, August 6, 2018 (Press release, CytRx, JUL 30, 2018, View Source [SID1234527969]). CytRx executives Eric L. Curtis, President and Chief Operating Officer, and John Caloz, Chief Financial Officer, will hold a conference call and webcast beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on that day to discuss the financial results as well as provide an overview of corporate achievements of both CytRx Corporation and Centurion BioPharma Corporation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

To access the conference call, dial (+1)844-358-6753 (U.S. and Canada) or (+1)216-562-0397 (international callers) and enter the conference ID number: 5991089. A live and archived webcast will be available in the News and Events/Events Calendar section of the company’s website, www.cytrx.com. A replay of the call and webcast will begin approximately two hours after the live call has ended. To access the replay, dial (+1)855-859-2056 (U.S. and Canada) or (+1)404-537-3406 (international callers) and enter the conference ID number: 5991089.

Arena Pharmaceuticals to Release Second Quarter 2018 Financial Results and Provide Corporate Update on Monday, August 6

On July 30, 2018 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that the Company will release its second quarter 2018 financial results and provide a corporate update on Monday, August 6, 2018, after the close of the U.S. financial markets (Press release, Arena Pharmaceuticals, JUL 30, 2018, View Source [SID1234527968]). The Company will host a conference call and live webcast with the investment community the same day at 4:30 p.m. EDT.

Conference Call & Webcast Information

When: August 6, 2018, 4:30 p.m. EDT

Dial-in: (877) 643-7155 (United States) or (914) 495-8552 (International)

Conference ID: 5986018

Please join the conference call at least 10 minutes early to register. You can access the live webcast under the investor relations section of Arena’s website at: www.arenapharm.com. A replay of the conference call will be archived under the investor relations section of Arena’s website for 30 days after the call.

Xencor to Host Second Quarter 2018 Financial Results Webcast and Conference Call on August 6, 2018

On July 30, 2018 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, reported that it will release second quarter 2018 financial results after the market closes on Monday, August 6, 2018 (Press release, Xencor, JUL 30, 2018, View Source [SID1234527967]). Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers, and referencing conference ID number 6399929. A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company’s website located at www.xencor.com. The webcast will be archived on the company website for 90 days.

Veracyte to Present at the Canaccord Genuity 38th Annual Growth Conference

On July 30, 2018 Veracyte, Inc. (Nasdaq: VCYT) reported that Bonnie H. Anderson, chairman and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference on Thursday, August 9, 2018 at 11:30 a.m. Eastern Time in Boston (Press release, Veracyte, JUL 30, 2018, View Source [SID1234527966]).

The live webcast of the presentation and a subsequent replay may be accessed by visiting Veracyte’s website at View Source The replay of the webcast will be available shortly after the conclusion of the presentation and archived on the company’s website for 90 days following the presentation.

FDA Grants Orphan Drug Designation to Surface Oncology’s SRF231 for the Treatment of Multiple Myeloma

On July 30, 2018 Surface Oncology (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s lead investigational candidate SRF231 for the treatment of patients with multiple myeloma (Press release, Surface Oncology, JUL 30, 2018, View Source [SID1234527965]). SRF231 is a fully human antibody that inhibits the activity of CD47, a protein overexpressed on many types of cancer cells which prevents them from being engulfed and eliminated by macrophages.

"While the potential applications for SRF231 in oncology are quite broad, we are particularly excited about the opportunity to provide benefit to patients with multiple myeloma. We have already demonstrated the ability of our antibody to increase phagocytosis of myeloma cells and to shrink tumors in preclinical models," said Rob Ross, M.D., chief medical officer of Surface Oncology. "Receiving orphan designation for SRF231 represents an important milestone as we continue to progress the program in the clinic in multiple myeloma and other cancer types."

The FDA’s Office of Orphan Products Development (OOPD) designates orphan status to drugs and biologics intended for the treatment of rare diseases or conditions that affect fewer than 200,000 people in the United States. The designation provides certain benefits to the drug developer including the potential for seven years of market exclusivity upon FDA approval, prescription drug user fee waivers and tax credits for qualified clinical trials.

SRF231 is currently being evaluated in a multi-center, open-label Phase I trial to assess safety and tolerability in multiple ascending doses with the goal of establishing a recommended dose for further study. Following the dose escalation phase, the company intends to evaluate the safety and efficacy of SRF231 in a targeted set of solid and hematologic malignancies.

ABOUT SRF231

SRF231 is a fully human monoclonal antibody therapeutic targeting CD47, a protein overexpressed on many cancer cells which prevents them from being engulfed and eliminated by macrophage mediated phagocytosis. SRF231 preclinical results presented at the 2016 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) and the American Society of Hematology (ASH) (Free ASH Whitepaper) meetings demonstrated that SRF231 has potent anti-tumor activity preclinically in several different tumor models and in combination with existing cancer modalities. Importantly, preclinical studies also showed that SRF231 does not induce hemagglutination, an important potential safety advantage.